The glucagon receptor raises theoretical concerns about heart rate increases (glucagon is known to increase heart rate), but clinical trial data has not shown significant safety issues in this regard so far
The activation of both TNFR1 and TNFR2 may induce c-Jun N-terminal kinase (JNK) [103] and the p38 MAPK pathways [104, 105]
Its critical to note that while some plant compounds may indirectly influence GLP-1 pathways or mimic some GLP-1 effects, they are not equivalent to pharmaceutical GLP-1 receptor agonists, Dr
Learn more: microdosing GLP-1s vs full therapeutic dosing If youre unsure where you fit, it can help to think about how your body typically responds to medication and hormone changes
What the research shows: A phase 2 randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine (Jastreboff et al., 2023) enrolled 338 adults with obesity